[go: up one dir, main page]

AU2002352420A1 - Pyrazine compounds and pharmaceutical compositions containing them - Google Patents

Pyrazine compounds and pharmaceutical compositions containing them

Info

Publication number
AU2002352420A1
AU2002352420A1 AU2002352420A AU2002352420A AU2002352420A1 AU 2002352420 A1 AU2002352420 A1 AU 2002352420A1 AU 2002352420 A AU2002352420 A AU 2002352420A AU 2002352420 A AU2002352420 A AU 2002352420A AU 2002352420 A1 AU2002352420 A1 AU 2002352420A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
compositions containing
pyrazine compounds
pyrazine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002352420A
Inventor
Anna Ingrid Kristina Berggren
Johan Michael Wilsterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002352420A1 publication Critical patent/AU2002352420A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
AU2002352420A 2001-12-19 2002-12-18 Pyrazine compounds and pharmaceutical compositions containing them Abandoned AU2002352420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0104332-2 2001-12-19
SE0104332A SE0104332D0 (en) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005736 WO2003051850A1 (en) 2001-12-19 2002-12-18 Pyrazine compounds and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
AU2002352420A1 true AU2002352420A1 (en) 2003-06-30

Family

ID=20286431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002352420A Abandoned AU2002352420A1 (en) 2001-12-19 2002-12-18 Pyrazine compounds and pharmaceutical compositions containing them

Country Status (4)

Country Link
AU (1) AU2002352420A1 (en)
SE (1) SE0104332D0 (en)
TW (1) TW200410693A (en)
WO (1) WO2003051850A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314049D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1644335A4 (en) 2003-07-11 2008-06-04 Bristol Myers Squibb Co Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
BRPI0507120A (en) 2004-01-28 2007-06-19 Hoffmann La Roche compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
KR100896353B1 (en) 2004-11-09 2009-05-08 에프. 호프만-라 로슈 아게 Dibenzosuberone derivatives
RU2404164C2 (en) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Pyridine-3-carboxamide derivatives as cb1 inverse agonists
AU2006236387A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
JP2009528266A (en) * 2006-01-18 2009-08-06 シェーリング コーポレイション Cannabinoid receptor modifier
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
FR2904827B1 (en) * 2006-08-11 2008-09-19 Sanofi Aventis Sa 5,6-BISARYL-2-PYRIDINE CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE AS UROTENSIN II RECEPTOR ANTIGANISTS
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
AU2007304365A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PL2114933T3 (en) 2007-01-04 2012-02-29 Prosidion Ltd Piperidine gpcr agonists
US20100048625A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
AR064735A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
AR064736A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
FR2927330B1 (en) * 2008-02-07 2010-02-19 Sanofi Aventis 5,6-BISARYL-2-PYRIDINE CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE AS ANTAGONISTS OF UROTENSIN II RECEPTORS
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397859A4 (en) * 1987-11-12 1990-12-19 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
JPH06501926A (en) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 heterocyclic compound

Also Published As

Publication number Publication date
WO2003051850A1 (en) 2003-06-26
TW200410693A (en) 2004-07-01
SE0104332D0 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
AU2002352420A1 (en) Pyrazine compounds and pharmaceutical compositions containing them
AU2002335536A1 (en) Pyrimidine compound and medicinal composition thereof
AU2002306269A1 (en) N-arylphenylacetamide derivatives and pharmaceutical composition containing the same
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
AU2002313236A1 (en) Medicinal compositions
IL157731A0 (en) Caboxylic acid derivatives and pharmaceutical compositions containing the same
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
HUP0401950A3 (en) Pyrimidine derivatives and pharmaceutical compositions containing that compounds
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
AU2002302147A1 (en) Pharmaceutical composition
AU2002257582A1 (en) Pharmaceutical formulation
IL158671A0 (en) Benzyloxy derivatives and pharmaceutical compositions containing the same
AU2002258221A1 (en) Medicinal composition
AU2002360117A1 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
AU2002252981A1 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2001274171A1 (en) Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
AU2002246658A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2002354460A1 (en) Medicinal composition
AUPR529701A0 (en) Pharmaceutical composition
AU2002346223A1 (en) Medicinal compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase